Related Experiment Video
Updated: Nov 10, 2025
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
[Efficacy of Micro-Transplantation Consolidation Therapy for Patients with Acute Myeloid Leukemia after Complete
Li-Xiao Song1, Shan-Dong Tao1, Yuan Deng1
1Department of Hematology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu Province, China,Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
Objective:
To investigate the efficacy and safety of micro-transplantation in acute myeloid leukemia (AML).
Methods:
The clinical data of 13 adult AML patients who received micro-transplantation as consolidation therapy from July 2014 to October 2019 was retrospectively analyzed, and the adverse reactions and efficacy of micro-transplantation were followed up.
Results:
Eight patients received micro-transpantation were still in complete remission, 5 patients relapsed after micro-transplantation, 1 of them received umbilical cord blood micro-transplantation after remission by reinduction, and all of the 13 patients have survived till now. The median overall survival time was 13 months, and the median relapse-free survival time was 12 months. All 13 patients developed grade 2-4 hematological adverse reactions. The median recovery time of neutrophils and platesets was 13 (11-15) and 15 (13-17) days, respectively. None of the 13 patients developed acute or chronic graft versus host disease. Twelve patients suffered from different infections, however, there were no serious organ function injury complications happened.
Conclusion:
The micro-transplomtation of HLA-incompatible stem cells derived from peripheral blood or umbilical and blood is an effective regimen for the consolidation therapy of AML, especially for the patients suffered from low and moderate risk of AML or the aged AML patients.
Insights
Micro-transplantation shows promise as consolidation therapy for acute myeloid leukemia (AML), with all patients surviving and many maintaining remission. While hematological side effects occurred, serious complications were avoided, indicating a favorable safety profile.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- Acute myeloid leukemia (AML) is a serious hematologic malignancy.
- Consolidation therapy aims to prevent relapse after initial treatment.
- Micro-transplantation is an emerging therapeutic strategy.
Purpose of the Study:
- To evaluate the efficacy and safety of micro-transplantation for AML consolidation.
- To assess survival and relapse rates post-micro-transplantation.
- To document adverse reactions associated with the procedure.
Main Methods:
- Retrospective analysis of 13 adult AML patients receiving micro-transplantation.
- Data collected from July 2014 to October 2019.
- Follow-up on adverse reactions and treatment efficacy.
Main Results:
- Eight patients remained in complete remission; five relapsed.
- All 13 patients survived with a median overall survival of 13 months.
- Grade 2-4 hematological adverse reactions were common, but no graft-versus-host disease or serious organ injury occurred.
Conclusions:
- Micro-transplantation using HLA-incompatible stem cells is effective for AML consolidation.
- It is particularly beneficial for low/moderate-risk or elderly AML patients.
- The procedure demonstrates a manageable safety profile for AML treatment.
